Insider · CIK 0001210905
Paul D Rubin
Files at BIOA (BioAge Labs, Inc.). First filing Dec 5, 2025, latest Apr 3, 2026.
Paul D Rubin files SEC Form 4 as officer at BIOA (BioAge Labs, Inc.). Since Dec 5, 2025, Paul D Rubin has reported 0 open-market buys worth $0 and 6 open-market sells worth $1.5M, the latest filed on Apr 3, 2026.
A track record needs three past buys with six months of prices behind them; Paul D Rubin has 0, so none is measured yet.
The newest scored trade: sold $157k of BIOA on Apr 1, 2026, filed Apr 3, 2026, scored 11 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 6 sells worth $1.5M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
BIOA: BioAge Labs, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 11Weak | BioAge Labs, Inc. | $157k 8,820 shares | -100% | +483% from low-23% from high | |
| 11Weak | BioAge Labs, Inc. | $151k 7,433 shares | -100% | +614% from low-5% from high | |
| 11Weak | BioAge Labs, Inc. | $139k 7,433 shares | -100% | +561% from low-12% from high | |
| 25Weak | BioAge Labs, Inc. | $95k 7,433 shares | -100% | +322% from low-9% from high | |
| 12Weak | BioAge Labs, Inc. | $216k 18,000 shares | -100% | +297% from low0% from high | |
| 21Weak | BioAge Labs, Inc. | $702k 68,897 shares | -100% | +245% from low-48% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Apr 1, 2026 | BIOA BioAge Labs, Inc. | 8,820 0.02% of outstanding | $157k | Apr 1, 2026 | $384k |
| Mar 2, 2026 | BIOA BioAge Labs, Inc. | 7,433 0.02% of outstanding | $149k | Mar 2, 2026 | $1.2M |
| Feb 2, 2026 | BIOA BioAge Labs, Inc. | 7,433 0.02% of outstanding | $139k | Feb 2, 2026 | $1.0M |
| Jan 2, 2026 | BIOA BioAge Labs, Inc. | 7,433 0.02% of outstanding | $100k | Jan 2, 2026 | $918k |
| Dec 9, 2025 | BIOA BioAge Labs, Inc. | 18,000 0.05% of outstanding | $216k | Dec 9, 2025 | $702k |
| Dec 4, 2025 | BIOA BioAge Labs, Inc. | 68,897 0.19% of outstanding | $702k | Dec 4, 2025 | none |
Transactions
Every row this insider has filed, 28 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 1, 2026 | BIOA BioAge Labs, Inc. | MOption exercise Common Stock10b5-1 | +5,437 | $4.11 | $22k | 5,437 | Apr 3, 2026 |
| Apr 1, 2026 | BIOA BioAge Labs, Inc. | MOption exercise Common Stock10b5-1 | +3,383 | $6.57 | $22k | 8,820 | Apr 3, 2026 |
| Apr 1, 2026 | BIOA BioAge Labs, Inc. | SOpen-market sale Common Stock10b5-1 | -8,820 | $17.81 | $157k | 0 | Apr 3, 2026 |
| Apr 1, 2026 | BIOA BioAge Labs, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,437 | $0.00 | $0 | 0 | Apr 3, 2026 |
| Apr 1, 2026 | BIOA BioAge Labs, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,383 | $0.00 | $0 | 0 | Apr 3, 2026 |
| Mar 2, 2026 | BIOA BioAge Labs, Inc. | MOption exercise Common Stock10b5-1 | +5,433 | $4.11 | $22k | 5,433 | Mar 3, 2026 |
| Mar 2, 2026 | BIOA BioAge Labs, Inc. | MOption exercise Common Stock10b5-1 | +2,000 | $6.57 | $13k | 7,433 | Mar 3, 2026 |
| Mar 2, 2026 | BIOA BioAge Labs, Inc. | SOpen-market sale Common Stock10b5-1 | -7,433 | $20.30 | $151k | 0 | Mar 3, 2026 |
| Mar 2, 2026 | BIOA BioAge Labs, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,433 | $0.00 | $0 | 5,437 | Mar 3, 2026 |
| Mar 2, 2026 | BIOA BioAge Labs, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,000 | $0.00 | $0 | 3,383 | Mar 3, 2026 |
| Feb 17, 2026 | BIOA BioAge Labs, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +110,000 | $0.00 | $0 | 110,000 | Feb 19, 2026 |
| Feb 2, 2026 | BIOA BioAge Labs, Inc. | MOption exercise Common Stock10b5-1 | +5,433 | $4.11 | $22k | 5,433 | Feb 3, 2026 |
| Feb 2, 2026 | BIOA BioAge Labs, Inc. | MOption exercise Common Stock10b5-1 | +2,000 | $6.57 | $13k | 7,433 | Feb 3, 2026 |
| Feb 2, 2026 | BIOA BioAge Labs, Inc. | SOpen-market sale Common Stock10b5-1 | -7,433 | $18.75 | $139k | 0 | Feb 3, 2026 |
| Feb 2, 2026 | BIOA BioAge Labs, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,433 | $0.00 | $0 | 10,870 | Feb 3, 2026 |
| Feb 2, 2026 | BIOA BioAge Labs, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,000 | $0.00 | $0 | 5,383 | Feb 3, 2026 |
| Jan 2, 2026 | BIOA BioAge Labs, Inc. | MOption exercise Common Stock10b5-1 | +5,433 | $4.11 | $22k | 5,433 | Jan 6, 2026 |
| Jan 2, 2026 | BIOA BioAge Labs, Inc. | MOption exercise Common Stock10b5-1 | +2,000 | $6.57 | $13k | 7,433 | Jan 6, 2026 |
| Jan 2, 2026 | BIOA BioAge Labs, Inc. | SOpen-market sale Common Stock10b5-1 | -7,433 | $12.85 | $95k | 0 | Jan 6, 2026 |
| Jan 2, 2026 | BIOA BioAge Labs, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,433 | $0.00 | $0 | 16,303 | Jan 6, 2026 |
| Jan 2, 2026 | BIOA BioAge Labs, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,000 | $0.00 | $0 | 7,383 | Jan 6, 2026 |
| Dec 9, 2025 | BIOA BioAge Labs, Inc. | MOption exercise Common Stock10b5-1 | +18,000 | $6.57 | $118k | 18,000 | Dec 11, 2025 |
| Dec 9, 2025 | BIOA BioAge Labs, Inc. | SOpen-market sale Common Stock10b5-1 | -18,000 | $12.00 | $216k | 0 | Dec 11, 2025 |
| Dec 9, 2025 | BIOA BioAge Labs, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -18,000 | $0.00 | $0 | 9,383 | Dec 11, 2025 |
| Dec 4, 2025 | BIOA BioAge Labs, Inc. | MOption exercise Common Stock10b5-1 | +68,897 | $4.11 | $283k | 68,897 | Dec 5, 2025 |
| Dec 4, 2025 | BIOA BioAge Labs, Inc. | SOpen-market sale Common Stock10b5-1 | -68,897 | $10.19 | $702k | 0 | Dec 5, 2025 |
| Dec 4, 2025 | BIOA BioAge Labs, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -68,897 | $0.00 | $0 | 21,736 | Dec 5, 2025 |
| Feb 18, 2025 | BIOA BioAge Labs, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Feb 20, 2025 |
Questions about Paul D Rubin
Answered from the filings on this page, as of the latest one.
Is Paul D Rubin buying or selling?
In the last 12 months Paul D Rubin reported 0 open-market buys worth $0 and 6 open-market sells worth $1.5M on SEC Form 4; the latest was sold $157k of BIOA on Apr 1, 2026. Grants, option exercises and tax withholding are not counted.
How did Paul D Rubin's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Paul D Rubin has 0.
Where does Paul D Rubin file Form 4?
Paul D Rubin has filed Form 4 at BIOA (BioAge Labs, Inc.) as Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.